<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39595">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590939</url>
  </required_header>
  <id_info>
    <org_study_id>50213</org_study_id>
    <nct_id>NCT02590939</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial on Acute Treatment of Migraine With the Cefaly速 Device</brief_title>
  <official_title>Multi-center, Double-blind, Randomized, Sham-controlled Trial on the Acute Treatment of Migraine With the Cefaly速 Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cefaly Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cefaly Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the efficacy of the Cefaly速 device as an acute
      treatment of migraine attack in adult patients. The patients will be applied either an
      active or placebo external neurostimulation for 1 hour during a migraine attack, and will
      report the pain on a visual analog scale before and after the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score 1-hour</measure>
    <time_frame>1 hour</time_frame>
    <description>Mean change of pain score (measured on a visual analog scale) at 1 hour compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication 2 hours</measure>
    <time_frame>2 hours</time_frame>
    <description>Proportion of patients not having required rescue medication at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 2 hours</measure>
    <time_frame>2 hours</time_frame>
    <description>Mean change of pain score (measured on a visual analog scale) at 2 hours compared to baseline (if rescue therapy was not used)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients not having required rescue medication within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Mean change of pain score (measured on a visual analog scale) at 24 hours compared to baseline (if rescue therapy was not used)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Active device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 minutes of active external trigeminal nerve stimulation with a CEFALY device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham device</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 minutes of placebo external trigeminal nerve stimulation with a CEFALY device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CEFALY Active</intervention_name>
    <description>Active external trigeminal nerve stimulation</description>
    <arm_group_label>Active device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CEFALY Placebo</intervention_name>
    <description>Placebo external trigeminal nerve stimulation</description>
    <arm_group_label>Sham device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of episodic or chronic migraine with or without aura meeting the diagnostic
             criteria listed in ICHD-III beta (2013) section 1, migraine, with the exception of
             ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine,
             ophthalmoplegic migraine, migrainous infarction)

          -  Having a migraine attack lasting at least 3 hours

          -  Migraine pain intensity stabilized for at least 1 hour

          -  Frontal, retro-, or peri- orbital headache.

        Exclusion Criteria:

          -  Pregnant women

          -  Patients having received Botox treatment in the prior 4 months

          -  Patients having received supraorbital nerve blocks in the prior 4 months

          -  Diagnosis of other primary or secondary headache disorders, except of Medication
             Overuse Headache

          -  Patients with only temporal or occipital headache

          -  Patients using opioid medication

          -  Patients having taken abortive migraine medication in the prior 3 hours

          -  Allodynia: intolerance to supraorbital neurostimulation (allodynia) that makes the
             treatment not applicable (the patients will be excluded if they are unable to
             tolerate the first 5 minutes of neurostimulation).

          -  Implanted metal or electrical devices in the head

          -  Cardiac pacemaker or implanted or wearable defibrillator

          -  Patient having had a previous experience with Cefaly速
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Chou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Casadei</last_name>
    <phone>(212) 305-3937</phone>
    <email>cc3825@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey FRACZKIEWICZ</last_name>
      <phone>203-785-3490</phone>
      <email>lindsey.fraczkiewicz@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Deena KURUVILLA, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rowe Neurology Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214-9836</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh KRESHEL</last_name>
      <phone>913-827-4262</phone>
      <email>lkreshel@neurokc.com</email>
    </contact>
    <investigator>
      <last_name>Dana WINEGARNER, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla CASADEI</last_name>
      <phone>212-305-3937</phone>
      <email>cc3825@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Denise CHOU, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>October 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
